JERSEY CITY, N.J.--(BUSINESS WIRE)--Next generation polymer technologies for the controlled delivery of drugs and tailor-made product concepts for topical delivery to the eye offer major market opportunities for new and/or improved treatments for a variety of chronic inflammatory ocular conditions, said Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases. Company scientists and collaborators are this week presenting data on a proprietary topical product and new bioerodible polymer/drug approaches for the treatment of dry eye and other inflammatory eye diseases at the 2008 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), which is taking place from April 27 – May 1 in Fort Lauderdale, Florida.
